Xentria Meitheal The Key to Enhanced Collaboration and Growth

In June we entered a commercial agreement for XTMAB-16 with Meitheal Pharmaceuticals. Xentria received an up-front payment of $60 million ... ... Meitheal Pharmaceuticals was the largest, rare disease focused deal in June. Meitheal gained exclusive rights to commercialize Xentria's ... Tom Shea, Chief Executive Officer at Meitheal Pharmaceuticals, based in Chicago, United States. Previously, he served as Chief Executive Officer of Xentria. Perkins Coie Advises Xentria in Multi-Year Licensing Agreement with Meitheal to Market Xentria's Novel Biologic to Treat Pulmonary Sarcoidosis · Home ... ... Xentria while at Meitheal Pharmaceuticals in a deal valued near $700 million. Jay holds a B.A. in Biology from William Jewell College and an M.B.A. from the ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America. Endpoints News - Jun 27, 2023. Companies are right to embrace ... Xentria Entered into an Exclusive Multi-Year License Agreement with Meitheal to Commercialize XTMAB-16 for Pulmonary Sarcoidosis in North America. Shots:. Historic milestone for our company ! 证券之星 2023-06-27 22:45:15. 【资料图】. 健友股份公告，公司全资子公司香港健友(被许可方代表)及香港健友控股子公司Meitheal(被许可方)拟与Xentria签署许可 ...